iwCLL 2023 | Novel inducers of apoptosis in double-refractory CLL cells
Deepa Sampath
• 6 Oct 2023
Deepa Sampath, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses her work in identifying novel targets in chronic lymphocytic leukemia (CLL) cells which are double-refractory to both ibrutinib and venetoclax. Using long-read and short-read sequencing of CLL cells, Bcl-xL and BCL2 have been identified as targets for novel compounds to induce apoptosis of the malignant cells. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
